Genital lichen sclerosus (LS) is usually managed with potent topical corticosteroids. There is a small (<5%) increased risk of skin cancer and long-term follow-up is recommended. We audited patients discharged to the care of their general practitioner (GP) from our regional vulval clinic. Only 29% had seen their GP in the last 12 months; 53% self-examined; 48% were unaware of the need to report abnormalities immediately; 24.4% were unaware of the recommended duration of use of their 30 g tube of steroid and only 66.7% were aware of the risk of skin cancer. Further education of both LS patients and their family practitioners is required.
DalzielKL, MillardPR, WojnarowskaF. The treatment of vulvar lichen sclerosus with a very potent topical corticosteroid (clobetasol propionate 0.05%) cream. Br J Dermatol1991;124:461–4
2.
WalkdenV, ChiaY, WojnarowskaF. The association of squamous cell carcinoma and lichen sclerosus; implications for follow up. J Obstet Gynaecol1997;17:551–3
3.
NeillSM, LewisFM, TatnallFM, CoxNH. British Association of Dermatologists' Guidelines for the Management of Lichen Sclerosus 2010. Br J Dermatol2010;147:640–9
4.
BalasubramanianP, LewisFM. Long-term follow-up of patients with lichen sclerosus: does it really happen?J Obstet Gynaecol2007;27:282
